ArticleAsia-Pacific journal of clinical oncology2026
Real-World Efficacy of Postoperative Adjuvant Nivolumab in High-Risk Urothelial Carcinoma: A Retrospective Comparative Study in an Asian Population.
Article in Asia-Pacific journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Real-World Efficacy of Postoperative Adjuvant Nivolumab in High-Risk Urothelial Carcinoma: A Retrospective Comparative Study in an Asian Population.Asia-Pacific journal of clinical oncology · 2026Article
- Treatment Patterns and Outcomes After Recurrence Following Adjuvant Nivolumab for Urothelial Carcinoma: An AGEHA Real-World Study.International journal of urology : official journal of the Japanese Urological Association · 2026Observational
- Clinical benefits, tolerability, and risk factors of adjuvant nivolumab for muscle-invasive bladder cancer.Translational andrology and urology · 2026Article
- Real-world Feasibility of Adjuvant Nivolumab for High-risk Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the real-world effectiveness of adjuvant nivolumab following radical surgery in patients with high-risk urothelial carcinoma, using historical data for comparison. MATERIALS AND
methodsPatients who underwent radical surgery at our institution were retrospectively analyzed. They were divided into two groups: one group received adjuvant nivolumab, and the other received no adjuvant therapy. Oncological outcomes, adverse events, and treatment completion rates were assessed.
resultsA total of 158 patients were included: 20 in the adjuvant nivolumab group and 138 in the control group. The median observation periods were 20.4 months in the nivolumab group and 36.7 months in the control group. The nivolumab group showed significantly improved recurrence-free survival compared to the control group (hazard ratio: 0.21; 95% confidence interval: 0.10-0.42; p = 0.01). Although overall survival tended to improve in the nivolumab group, the difference was not statistically significant (hazard ratio: 0.32; 95% confidence interval: 0.01-1.01; p = 0.22). Multivariate analysis confirmed adjuvant nivolumab as a significant favorable prognostic factor for recurrence-free survival (hazard ratio: 0.18; 95% confidence interval: 0.044-0.73; p = 0.017). One-year treatment was completed in 55.0% of patients. Adverse events led to discontinuation in 25.0%, with major events including interstitial lung disease (three patients), hormonal disorders such as isolated adrenocorticotropic hormone deficiency (2), rash (3), hypothyroidism (1), and hepatitis (1).
conclusionAdjuvant nivolumab demonstrated clinical benefit in Asian patients with high-risk urothelial carcinoma in a real-world setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.